Cortex Business Solutions has a 94 per cent upside, Beacon Securities says

Cortex CEO Joel Leetzow
E-invoicing company Cortex Business Solutions (Cortex Stock Quote, Chart TSXV:CBX) is starting to see the benefits of its Powervision acquisition, says analyst Gabriel Leung of Beacon Securities, who on Friday upped his target price in response to the company’s recently released earnings.

Calgary-based Cortex Business Solutions reported its fiscal first quarter 2019 financials last week, producing revenue and EBITDA of $3.3 million and $643,000, respectively, with President and CEO Joel Leetzow pointing to the gains made through acquiring software company Powervision, a $7-million deal which closed this past September.

“With our first months now behind us after the Powervision acquisition, we are already starting to see the synergies that we had expected from combining the two companies,” said Leetzow, in a press release. “We have made two new sales of the complete Cortex platform since the acquisition and our pipeline for the combined solution is growing rapidly.”

The Q1 top and bottom lines came in slightly above Leung’s estimates, which were $3.1 million and $466,000, respectively. Drilling down, Leung highlighted the company’s recurring access and usage fees which were up 16 per cent year-over-year to $3.3 million, with 97 buyers in the network (down from 99 last quarter) and active suppliers at 9,386 (up from 9,160 last quarter.

“Overall, we think fiscal Q1 was a strong start to the Powervision integration both in terms of financials and new customer and pipeline signups,” says Leung, in an update to clients last week. “We are maintaining our Buy rating, but increasing our target price to $7.00 (was $6.50), which is based on 15x FY20e EV/EBITDA.”

Leung’s $7.00 target represented a 94 per cent projected return on investment as of publication date.

Tagged with: cbx
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

BCE upgraded to “Buy” at TD

TD Cowen analyst Vince Valentini says the recent pullback in BCE (BCE Stock Quote, Chart, News, Analysts, Financials TSX:BCE) shares… [Read More]

7 hours ago

This analyst just upgraded Versabank to “Buy”

Roth Capital Partners analyst Craig Irwin says VersaBank’s (VBNK Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) early commercial rollout of… [Read More]

7 hours ago

This analyst just raised his price target on Rocket Lab USA

Roth Capital Partners analyst Suji Desilva says Rocket Lab USA’s (Rocket Lab USA Stock Quote, Chart, News, Analysts, Financials NASDAQ:RKLB)… [Read More]

1 day ago

Why this analyst just chopped his price target on Medicenna Therapeutics

Research Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical… [Read More]

1 day ago

Firan Technology: Buy, Sell or Hold?

Beacon Securities analyst Russell Stanley says Firan Technology Group’s (Firan Technology Group Stock Quote, Chart, News, Analysts, Financials TSX:FTG) new… [Read More]

1 day ago

Magellan Aerospace is still undervalued, this fund manager says

LionGuard Capital Management CEO and CIO Andrey Omelchak says Magellan Aerospace (Magellan Aerospcace Stock Quote, Chart, News, Analysts, Financials TSX:MAL)… [Read More]

3 days ago